Lenvatinib Mesylate Intermediate CAS 205448-65-3 Kemurnian >98,0% (HPLC) Pabrik

Katrangan singkat:

Jeneng Kimia: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate

CAS: 205448-65-3

Kemurnian: >98,0% (HPLC)

Penampilan: Bubuk Putih nganti Kuning

Penengah saka Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Detail Produk

Produk sing gegandhengan

Tag produk

katrangan:

Sifat Kimia:

Jeneng Kimia Metil 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate
sinonim 1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;Lenvatinib Intermediate 3
Nomer CAS 205448-65-3
Nomer CAT RF-PI1973
Status Simpenan Ing Simpenan, Kapasitas Produksi 50 MT / Taun
Formula Molekul C12H11NO4
Bobot Molekul 233.22
Titik didih 421,0 ± 45,0 ℃
Kapadhetan 1,267±0,060 g/cm3
Merk Kimia Ruifu

Spesifikasi:

Item Spesifikasi
Penampilan Bubuk Putih nganti Kuning
Kemurnian / Metode Analisis > 98,0% (HPLC)
Mundhut ing Pangatusan <1.00%
Sisa ing Ignition <0,50%
Total Impurities <2.00%
H-NMR Conforms kanggo Struktur
Test Standar Standar Perusahaan
Panggunaan Perantara Farmasi

Paket & Panyimpenan:

Paket: Botol, tas Aluminium foil, 25kg / Karton Drum, utawa miturut kabutuhan pelanggan

Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya lan Kelembapan

Kaluwihan:

1

FAQ:

Aplikasi:

Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) minangka perantara saka Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib, sing didol nganggo jeneng merek Lenvima antara liya, minangka obat anti-kanker kanggo perawatan kanker tiroid tartamtu lan uga kanker liyane.Iki dikembangake dening Eisai Co. lan tumindak minangka inhibitor kaping kinase marang kinase VEGFR1, VEGFR2 lan VEGFR3.Lenvatinib disetujoni (wiwit 2015) kanggo perawatan kanker tiroid sing beda-beda sing kedadeyan sacara lokal utawa metastatik, progresif, lan ora nanggapi perawatan karo yodium radioaktif (radioiodine).Ing Mei 2016, US Food and Drug Administration (FDA) nyetujoni (ing kombinasi karo everolimus) kanggo perawatan karsinoma sel ginjel lanjut sawise siji terapi anti-angiogenik sadurunge.Obat kasebut uga disetujoni ing AS lan ing Uni Eropa kanggo karsinoma hepatoseluler sing ora bisa diilangi kanthi bedah ing pasien sing durung nampa terapi kanker kanthi tutuk utawa injeksi.

Tulis pesen sampeyan ing kene lan kirimake menyang kita